NOV 17, 202668 MINS READ
The chemical synthesis of creatine phosphate has evolved significantly since the pioneering work of Zeile and Fawaz in 1938, who first achieved phosphorylation of creatine using phosphorus oxychloride (POCl₃) in strongly alkaline media 8. Contemporary chemical routes primarily employ POCl₃ as the phosphorylating agent, reacting with either creatine or creatinine (creatine anhydride) under controlled conditions to introduce the phosphate group 4. The classical method involves mixing creatine with POCl₃ in alkaline aqueous solution at low temperature (0–10°C), followed by pH adjustment and thermal reaction to obtain creatine phosphate solution 1. However, this approach historically suffered from poor yields and difficult separation due to the formation of Na₃PO₄ precipitates that complicate stirring and cooling operations 5.
Recent innovations have addressed these limitations through intermediate purification strategies. One advanced method synthesizes creatinine phosphoryl chloride as an intermediate by condensing creatinine with POCl₃, followed by purification in halogenated hydrocarbon solvents (solvent A) and crystallization with aliphatic hydrocarbons (solvent B) to remove impurities 15. This purified intermediate is then hydrolyzed in sodium hydroxide solution to yield high-purity disodium creatine phosphate tetrahydrate with yields reaching 91.6% and purity exceeding 99.68% 15. Another approach utilizes chlorophosphoric acid (prepared from POCl₃ and water at 0–10°C) reacting with S-methyl isothiourea sulfate in dipolar aprotic solvents to form phosphorylated S-methyl isothiourea, which subsequently reacts with sarcosine to produce creatine phosphate 12. This barium-free process eliminates heavy metal contamination, generates only gaseous by-products, simplifies post-processing, and significantly reduces production costs while achieving high yields 12.
The stoichiometry and reaction conditions critically influence product quality. Typical mass ratios of creatinine to POCl₃ range from 1:30 to 1:90, with excess POCl₃ being recoverable through vacuum distillation 15. Temperature control during phosphorylation (typically 20–60°C) and subsequent hydrolysis (often at elevated temperatures with precise pH adjustment to 8–9 using NaOH or sodium methoxide) are essential to maximize conversion and minimize side reactions 412. The use of catalysts such as 4-dimethylaminopyridine (DMAP) and dehydrating agents like dicyclohexylcarbodiimide (DCC) in organic solvents (e.g., ethyl acetate) has been reported to enhance phosphorylation efficiency, with DCC forming insoluble dicyclohexylurea (DCU) that can be easily filtered out during alkaline hydrolysis, allowing direct precipitation of high-quality disodium creatine phosphate by adding ethanol to the aqueous solution 4. Solvent recycling (ethyl acetate and ethanol) further reduces waste discharge and operational costs 4.
Continuous-flow microreactor technology represents a paradigm shift in creatine phosphate synthesis, offering enhanced safety, efficiency, and scalability compared to traditional batch processes 10. In this approach, creatinine dissolved in dichloromethane (reservoir A) and POCl₃ (reservoir B) are fed into a microchannel reactor via precision pumps at controlled volumetric flow rates (e.g., 200 mL/min for reservoir A and 100 mL/min for reservoir B), with reaction temperature maintained at approximately 45°C to produce the phosphorylation condensation product 10. The reaction mixture is then concentrated under reduced pressure (−0.10 MPa at 55°C) to remove solvent, and residual POCl₃ is eliminated by dissolving the residue in toluene, cooling to 10–30°C to crystallize dichlorophosphoryl creatinine, and filtering 10.
The purified dichlorophosphoryl creatinine is redissolved in dichloromethane (reservoir C) and reacted with sodium hydroxide solution (reservoir D) in a second microchannel reactor to generate sodium creatine phosphate solution 10. This solution undergoes liquid-liquid extraction and phase separation, with the aqueous layer treated with activated cation-exchange resin to adjust pH to 9–10, followed by microfiltration and crystallization with 95% ethanol at 20–25°C, then cooling to 10–15°C for complete precipitation 10. This continuous-flow process significantly reduces POCl₃ usage and residual contamination, minimizes reaction by-products and phosphate salt impurities, improves reaction efficiency, and lowers costs while enhancing product safety 10. Molar yields based on anhydrous product can reach 91.6% with purity of 99.68% 10.
The integration of microchannel reactors provides superior heat and mass transfer, precise residence time control, and reduced reaction volumes, which collectively enhance selectivity and reproducibility. The ability to operate under continuous steady-state conditions also facilitates real-time monitoring and quality control, making this technology highly suitable for large-scale pharmaceutical manufacturing where consistency and regulatory compliance are paramount.
Enzymatic synthesis of creatine phosphate offers a biocatalytic alternative that mimics the natural biosynthetic pathway in muscle tissue, potentially providing higher specificity and milder reaction conditions 5. The enzymatic route involves incubating creatine and 3-phosphoglyceric acid with an aqueous muscle extract containing creatine kinase (CK) in the presence of a catalytic amount of adenosine triphosphate (ATP) in an alkaline medium 5. After incubation, the mixture is briefly heated to 70–100°C to denature enzymes and other proteins, and creatine phosphate is subsequently isolated 5. This method can produce creatine phosphate in practically unlimited quantities with excellent yields, overcoming the poor yields and operational difficulties associated with early chemical methods 5.
However, the enzymatic approach faces economic and technical challenges for industrial-scale production. Traditional enzymatic methods for analytical determination of creatine require highly expensive phosphoenolpyruvate and highly purified creatine phosphokinase, and the reaction can be inhibited by serum components 5. Furthermore, at the concentrations required for preparative synthesis, isolation of creatine phosphate becomes costly and complex 5. Despite these limitations, the enzymatic method remains valuable for producing research-grade material and for applications where the natural stereochemistry and absence of chemical by-products are critical. One Chinese manufacturer (Jilin Yinglian Biotechnology Co., Ltd.) has adopted enzymatic production using creatine kinase extracted from animal muscle, with ATP and creatine reacting under optimal enzyme conditions to synthesize creatine phosphate 12. This process fully simulates the in vivo synthesis pathway, though it does not fully resolve product separation and purification challenges 12.
Advances in enzyme engineering, such as the use of immobilized or recombinant creatine kinase with enhanced stability and activity, may improve the economic feasibility of enzymatic synthesis. Additionally, coupling enzymatic phosphorylation with in situ ATP regeneration systems (e.g., using acetate kinase and acetyl phosphate) could reduce the cost of the ATP cofactor, making enzymatic routes more competitive with chemical methods for certain applications.
Beyond native creatine phosphate, the synthesis of analogs such as cyclocreatine phosphate (CCrP) and creatinol O-phosphate has garnered significant research interest due to their enhanced pharmacological properties and potential therapeutic applications 23611. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) is efficiently phosphorylated in vitro and in vivo by creatine kinase to yield cyclocreatine phosphate, which can sustain high levels of myocardial ATP and delay ATP depletion during ischemia more effectively than creatine phosphate 61114. Cyclocreatine phosphate can be synthesized from inexpensive starting materials in stable form on a large scale (>100 g, >1 kg, or ≥10 kg) 611. The synthesis typically involves multi-step organic transformations, including conversion of sarcosine esters with guanylating agents protected by t-butoxycarbonyl (t-Boc) groups to form (Boc)₂-creatine esters, followed by basic hydrolysis to yield (Boc)₂-creatine, which can then be conjugated or phosphorylated 9.
Creatinol O-phosphate synthesis involves reacting creatinol sulfate with sulfuric acid to form a protected creatinol sulfate intermediate, which is then reacted with phosphorylating agents such as P₂O₅, ClPO₃H₂, or POCl₃ to form creatinol O-phosphate 23. The creatinol O-phosphate solution is subsequently crystallized to obtain the pure compound 23. This analog acts similarly to creatine phosphate by donating its phosphate group to convert ADP to ATP in muscles, but it supplies energy more effectively, thereby reserving more energy in muscles, enhancing muscle strength and explosive force, increasing muscle flexibility, minimizing muscle damage, and delaying muscle fatigue 23. The yield rate for creatinol O-phosphate synthesis can reach approximately 44.67%, with further purification via barium carbonate and barium hydroxide 2.
Carboxylic biacyl creatine derivatives represent another class of creatine analogs designed to cross biological barriers by diffusion without requiring the creatine transporter, making them effective for treating diseases caused by creatine uptake deficiencies, such as creatine transporter deficiency, arginine-glycine amidinotransferase (AGAT) deficiency, and guanidinoacetate methyltransferase (GAMT) deficiency 7. These lipophilic derivatives can easily enter nerve cells and brain tissue, offering therapeutic potential for cerebral creatine deficiency syndromes 7. The synthesis of such derivatives involves protecting the creatine carboxyl group and introducing lipophilic acyl groups to enhance membrane permeability 79.
Prodrug strategies have also been developed to improve the bioavailability and cellular uptake of creatine phosphate. Membrane-permeable creatine phosphate prodrugs incorporate promoieties that mask the charged phosphate group, facilitating passive diffusion across cell membranes 1317. Once inside the cell, enzymatic or chemical cleavage releases the active creatine phosphate 1317. These prodrugs have shown promise in restoring cellular energy homeostasis following ischemic insults and in treating neurodegenerative disorders and genetic diseases affecting the creatine kinase system 1317. Synthesis of these prodrugs typically involves attaching promoieties to creatine phosphate analogs using established organic chemistry methods, with careful attention to stability and cleavage kinetics 13.
Achieving pharmaceutical-grade purity in creatine phosphate synthesis requires rigorous purification and quality control protocols. Traditional purification methods involved conversion to heavy metal salts (e.g., barium or calcium salts) or ion-exchange chromatography to remove inorganic phosphate impurities and unreacted starting materials 812. However, these methods are labor-intensive, costly, and can introduce heavy metal contamination 12. Modern barium-free processes eliminate this risk by using organic solvent crystallization and cation-exchange resin treatment to adjust pH and remove ionic impurities 41215.
Crystallization from aqueous ethanol is a widely adopted final purification step, yielding disodium creatine phosphate tetrahydrate with purity exceeding 99% 41015. The crystallization process typically involves cooling the aqueous solution to 10–20°C after ethanol addition, allowing slow crystal growth over 1–2 hours, followed by filtration and vacuum drying at 45–50°C 1015. Analytical methods for quality control include high-performance liquid chromatography (HPLC) to quantify creatine phosphate content and detect related substances, ion chromatography to measure inorganic phosphate and chloride impurities, and nuclear magnetic resonance (NMR) spectroscopy to confirm molecular structure 41015. Residual solvent analysis by gas chromatography (GC) ensures compliance with pharmacopeial limits for dichloromethane, ethyl acetate, and ethanol 410.
Water content determination by Karl Fischer titration is critical for the tetrahydrate form, as deviations can affect stability and dosage accuracy 1015. Heavy metal testing (e.g., by inductively coupled plasma mass spectrometry, ICP-MS) confirms the absence of barium, lead, and other toxic metals, particularly important for barium-free synthesis routes 1215. Microbial contamination is controlled through sterile filtration (0.22 μm) and endotoxin testing for parenteral formulations 16. Stability studies under accelerated conditions (40°C, 75% relative humidity) and long-term storage (25°C, 60% relative humidity) assess the shelf life and degradation pathways, guiding formulation development and packaging selection 16.
Creatine phosphate and its analogs have diverse applications in biomedical research and clinical therapy, primarily centered on their role in cellular energy metabolism and cardioprotection. Creatine phosphate is widely used as a myocardial protective agent and energy supplement in clinical settings, with efficacy approximately 316 times greater than fructose-1,6-diphosphate (FDP), demonstrating clear therapeutic effects and high safety 12. It is indicated for conditions involving myocardial ischemia, heart failure, myocardiosclerosis, degenerative cardiomyopathies, and anoxic states where rapid restoration of myocardial contractility is essential 816. Dosages for exerting biological properties in animals and humans are well-established, with parenteral formulations (intravenous or intramuscular) being the primary route of administration due to the compound's poor oral bioavailability 16.
In research contexts, creatine phosphate is employed to study energy metabolism, ATP synthesis, and the creatine kinase system in various tissues, including skeletal muscle, cardiac muscle, and brain 51214. Cyclocreatine and cyclocreatine phosphate have been investigated for their ability to delay ATP depletion during ischemia and restore cardiac function in models of hypothermic cardioplegic cardiac arrest (simulating bypass surgery), regional warm ischemia (simulating acute myocardial infarction), and global warm ischemia (simulating cardiac arrest) 611. Notably, cyclocreatine phosphate can exert beneficial effects even when administered after ischemia occurs, offering a therapeutic window for post-ischemic intervention 611.
Creatine phosphate analogs have also demonstrated antitumor activity by inhibiting tumor cell growth, likely through modulation of energy metabolism and interference with cellular proliferation pathways 14. Phosphorylcyclocreatine, provided as the disodium salt trihydrate (C₅H₈N₃O₅P·Na₂·3H₂O), exhibits improved solubility compared to the dilithium dihydrate form or cyclocreatine itself, facilitating formulation and administration 14. In neurodegenerative disease research, creatine phosphate prodrugs and analogs are being explored for their neuroprotective effects, particularly in conditions characterized by mitochondrial dysfunction and energy deficits, such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) 1317.
Genetic disorders affecting the creatine kinase system, including creatine transporter deficiency, AGAT deficiency, and GAMT deficiency, represent emerging therapeutic targets for creatine phosphate derivatives 713. Lipophilic creatine analogs that bypass the creatine transporter can restore cerebral creatine levels and ameliorate neurological symptoms in patients with transporter
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| CHONGQING SHENGHUAXI PHARMACEUTICAL CO. LTD. | Large-scale pharmaceutical manufacturing of high-purity disodium creatine phosphate tetrahydrate for myocardial protection and energy supplementation in clinical settings. | Continuous-Flow Creatine Phosphate Synthesis System | Achieves 91.6% molar yield with 99.68% purity using microchannel reactor technology, significantly reduces POCl3 usage and residual contamination, minimizes reaction by-products and phosphate salt impurities. |
| TAISHAN MEDICAL UNIVERSITY | Cost-effective synthesis of disodium creatine phosphate for pharmaceutical applications requiring high purity and reduced environmental impact. | DMAP-Catalyzed Phosphorylation Process | Utilizes 4-dimethylaminopyridine (DMAP) as catalyst and dicyclohexylcarbodiimide (DCC) as dehydrating agent in ethyl acetate solvent, achieving high single-step reaction yields with recyclable solvents and minimal wastewater discharge. |
| NANJING CUCCESS PHARMACEUTICAL CO. LTD. | Safe pharmaceutical-grade creatine phosphate production for myocardial protective agents without heavy metal contamination risks. | Barium-Free Creatine Phosphate Synthesis | Eliminates heavy metal contamination by using chlorophosphoric acid prepared from POCl3 reacting with S-methyl isothiourea sulfate in dipolar aprotic solvents, generates only gaseous by-products, simplifies post-processing with high yields. |
| NOUR HEART INC. | Cardioprotection in models of hypothermic cardioplegic cardiac arrest, regional warm ischemia (acute myocardial infarction), and global warm ischemia (cardiac arrest). | Cyclocreatine Phosphate (CCrP) | Delays ATP depletion during ischemia more effectively than creatine phosphate, can be synthesized on large scale (>1 kg) from inexpensive starting materials in stable form, effective even when administered after ischemia occurs. |
| UNIVERSITA' DEGLI STUDI DI GENOVA | Treatment of creatine transporter deficiency, AGAT deficiency, GAMT deficiency, and cerebral creatine deficiency syndromes in neurological disorders. | Carboxylic Biacyl Creatine Derivatives | Lipophilic derivatives cross biological barriers by diffusion without requiring creatine transporter, easily enter nerve cells and brain tissue, effective for treating creatine uptake deficiencies. |